Загрузка...
Directed Evolution of AAV Serotype 5 for Increased Hepatocyte Transduction and Retained Low Humoral Seroreactivity
Most recombinant adeno-associated virus (AAV) capsids utilized in liver gene therapy have significant levels of pre-existing neutralizing antibodies in the human population. These neutralizing factors limit the patient pools eligible for receiving AAV-mediated therapies. AAV serotype 5 (AAV5) does n...
Сохранить в:
| Опубликовано в: : | Mol Ther Methods Clin Dev |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Gene & Cell Therapy
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7773954/ https://ncbi.nlm.nih.gov/pubmed/33426144 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2020.10.010 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|